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Abstract
Purpose Progression of Barrett's esophagus (BE) to esopha-
geal adenocarcinoma (EAC) is associated with accumulated
genomic instability. Current risk stratification of BE for EAC
relies on histological classification and grade of dysplasia.
However, histology alone cannot assess the risk of patients
with inconsistent or non-dysplastic BE histology. We, there-
fore, examined the presence and extent of genomic instability
in advanced and less advanced BE histology using mutational
load (ML).
Methods ML summarized the presence and clonality of loss
of heterozygosity (LOH) mutations and the emergence of new
alleles, manifested as microsatellite instability (MSI) muta-
tions, in ten genomic loci around tumor suppressor genes
associated with EAC. The ML of 877 microdissected targets
from BE biopsies was correlated to their histology. Histolog-
ical targets were categorized into three levels: no ML, low
ML, and high ML.
Results Increasing ML correlated with increasingly severe
histology. By contrast, proportions of targets that lacked mu-
tations decreased with increasingly severe histology. A por-
tion of targets with non-dysplastic and low-grade histology
shared a similar ML as those with higher risk and EAC
disease. The addition of MSI characterization to ML helped
to differentiate the ML between advanced and less advanced
histology.
Conclusions Given that EAC is associated with accumulated
genomic instability, high ML in less severe histology may
identify BE disease at greater risk of progression to EAC. ML
may help to better manage BE in early histological stages and
when histology alone provides insufficient information.
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Introduction
Esophageal adenocarcinoma (EAC) exhibits the highest rate
of increasing incidence of any solid cancer in the US today,
and Barrett's esophagus (BE) represents a precursor of and
largest risk factor for EAC [1, 2]. The carcinogenesis of BE
has been associated with morphologic changes in esophageal
tissue as well as activation of oncogenes and inactivation of
tumor suppressor genes [2]. Studies have shown that variable
degrees of mutational change take place in the microsatellite
regions of tumor suppressor genes at the histological onset of
BE [3–7]. The cumulative buildup of various mutations has
been closely associated with the different histological grades
of BE and EAC [3, 4, 7]. Histological progression to EAC is
associated with a relatively poor prognosis, with a 5-year
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survival rate for regional cancer below 18 % [8]. Consequent-
ly, emphasis has been placed upon understanding the risk for
progression to EAC of each histological stage of BE such
that patients can be appropriately managed with inter-
vention or surveillance.
Accurate histological classification is essential for properly
detecting BE at its earliest stages. Guidelines currently define
BE as specialized intestinal metaplasia (IM) with goblet cells
and grade BE samples with the following progressive histo-
logical classifications: IM, indefinite for dysplasia (IND), low-
grade dysplasia (LGD), and high-grade dysplasia (HGD) [9].
The most advanced, HGD, has been associated with a greater
risk of progression to EAC [10–13].
Both BE and EAC can be readily identified by microscopic
examination, but the presence and different grades of dyspla-
sia can be difficult to diagnose due to challenges in discrim-
inating reactive epithelial atypia from true dysplasia [14–18].
The classification of IND is sometimes providedwhen cellular
atypia is observed, but the criteria for the histological diagno-
sis of dysplasia are not fully met. Poor orientation of the
histological sections and presence of inflammatory infiltrate
are among the most common factors interfering with the
pathologist's ability to differentiate between the presence or
absence of dysplasia. Inter-observer variability in the histo-
logical classification of BE has been reported by various
studies [14–18]. Most variability is linked to LGD [15], yet
some variability is also seen in cases of HGD [14], compli-
cating the decision as to how to clinically manage patients.
Non-dysplastic histological features are limited when it
comes to determining whether or not a case of BE is likely
to progress to cancer or remain stable, as there are no observ-
able non-dysplastic histological microscopic features that can
reveal a patient's likelihood of cancer progression. Because of
this uncertainty, many choose ablation interventions for low-
grade dysplastic and non-dysplastic BE, which has provoked
concerns about unnecessary healthcare expenditures [19, 20].
Supplementary diagnostic information that enables better
characterization of the risk for less advanced stages of BE
disease would be valuable in improving patient care and
controlling healthcare costs.
In this study, we aimed to provide additional infor-
mation to the histological classification of less advanced
stages of BE by showing the relationship between BE
histology and the presence and extent of genomic insta-
bility in multiple study cohorts. Previous investigation
has shown that three or more DNA abnormalities in less
advanced stages of BE are associated with a higher risk of
cancer progression [21]. Two of these abnormalities were loss
of heterozygosity (LOH) mutations in microsatellite regions
of the TP53 and CDKN2A tumor suppressor genes. Increasing
sizes of genetically instable clones with TP53 and CDKN2A
LOH have also been associated with increased risk of pro-
gression to EAC [22].
We therefore studied the presence and extent (clonality) of
genomic instability in advanced and less advanced BE histol-
ogy in a cross-sectional study of patients from multiple study
cohorts. Genomic instability was assessed by mutational load
(ML) in histological targets microdissected from BE patient
biopsy tissue. ML summarized the presence and extent of
LOH next to TP53 and CDKN2A as well as LOH in eight
additional genomic loci next to tumor suppressor genes. Mi-
crosatellite instability (MSI) around these tumor suppressor
genes was also included in the assessment of ML. Our results
demonstrate that histology-guided assessment for ML pro-
vides an objective measure of the presence and extent of
genomic instability. Assessment for ML provides an added
dimension to less advanced BE histology that could help to




Standard histological sections (4 μm thick) of formalin-fixed,
paraffin-embedded (FFPE) tissue were examined from 415 pa-
tients histologically known to have BE. Microdissection of 661
biopsy slides yielded 877 targets in total from three study sites,
each with IRB approval of their corresponding study protocol
(IRB# 26163, IRB #11-29, IRB # 5658 and IRB# 5629). All
patients in the study had previously undergone upper GI endos-
copy. Patients without evidence of BE were excluded.
Histological Classification
Hematoxylin and eosin (H&E)-stained, FFPE histology slides
underwent microscopic evaluation for the selection of targets
for subsequent microdissection. Each target was histologically
classified as follows: normal squamous epithelium, columnar
mucosa (COL), and, in order of increasing severity: IM, IND,
LGD, HGD, and EAC. BE histological classification began
with IM histology. A histological classification was assigned
based on pathologist review of tissue. All pathologists were
blinded to molecular results. In one study cohort from Nor-
walk Hospital, three pathologists classified the same micro-
dissected targets. Consensus diagnosis was defined as agree-
ment between at least two pathologists.
Microdissection
H&E-stained, FFPE slides were used as guides to
microdissect tissue (targets) with BE histology from one to
three unstained, serial FFPE slides of each patient. Microdis-
sected targets corresponded to distinct foci of tissue with EAC
histology, BE histology, COL histology, or normal epithelial
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histology, as identified by a pathologist. Normal epithelial and
COL targets were microdissected from the same FFPE slides
as targets with various histological classifications of BE or
EAC histology. Microscopic review confirmed the accuracy
of all microdissections.
Detection of LOH and MSI
Detection of LOH and new alleles consistent with MSI were
investigated at ten individual genomic loci, using a panel of 22
DNA markers associated with common tumor suppressor
genes relevant to BE [3, 23–27]. The presence of MSI at
BAT25 and BAT26 loci were also examined in a subset of
microdissected targets. LOH and MSI were assessed using
polymerase chain reaction (PCR) and quantitative capillary
electrophoresis of DNA extracted from each microdissected
target, as previous described [24, 25]. DNA markers for the
following chromosomal loci comprised the panel (associated
genes in parentheses): 1p (CMM1, L-myc), 3p (VHL,HoGG1),
5q (MCC, APC), 9p (CDKN2A), 10q (PTEN, MXI1), 17p
(TP53), 17q (NME1), 18q (DCC), 21q (TFF1 and PSEN2)
and 22q (NF2).
Quantitative PCR (qPCR) for housekeeping genes was
used to ensure there was sufficient, high quality DNA avail-
able for analysis prior to LOH andMSI analysis. The analyses
were performed on both BE microdissection samples as well
as internal controls (normal appearing squamous and COL),
which were all subject to equivalent formalin fixation and
histological processing. PCR amplification and subsequent
mutational analysis using quantitative capillary electrophore-
sis methods were then performed on all microdissected sam-
ples with adequate qPCR results.
To determine if each LOH analysis was assessable in each
patient, the informativeness (heterozygosity) of each LOH
marker in normal epithelial from each patient was first exam-
ined by quantitative capillary electrophoresis methods. Nor-
mal epithelial targets were also used to account for minor
differences in the amplification rates of the two-allele lengths
during PCR. PCR amplification and subsequent quantitative
capillary electrophoresis of DNA from each microdissected
target was then performed to assess LOH and MSI.
LOH was called "present" in microdissected targets when
there was a degree of allelic imbalance that was equal to or
beyond two standard deviations above the average difference
in allele peak heights for DNA in normal epithelial microdis-
section targets. The extent (clonality) of LOH was determined
using the ratio of allele peak heights in DNA from microdis-
sected targets, which is proportional to the amount of LOH
mutated DNA present in the sample [23–27]. All DNA spec-
imens with LOHwere tested in duplicate or triplicate to ensure
reproducibility. LOH mutations were considered high
clonality when >75 % of the DNA had LOH mutation and
low clonality when 50–75 % of the DNA had LOH mutation.
MSI was defined by the presence of additional minor, but
reproducible, peaks in the electropherograms after PCR am-
plification and subsequent quantitative capillary electrophore-
sis of DNA from each target. The minor peaks did not corre-
spond to either of the two major allele lengths present in
normal epithelial control DNA and were not accountable by
the presence of shadow band formation during capillary gel
electrophoresis. The minor peaks were reproducible through
replicate confirmatory PCR amplification and further quanti-
tative capillary electrophoresis testing.
Mutational Load
ML measured the presence and clonality of LOH muta-
tions and the presence of MSI at each genomic locus
examined. The presence and clonality of LOH mutation
at each genomic locus was determined for each micro-
dissected target. Low clonality LOH was defined as 50–
75 % of the DNA containing LOH, and high clonality
LOH was defined as >75 % of the DNA containing
LOH. All LOH mutations at a given genomic loci were
assigned a numerical value based on their low or high
clonality. A proportional value of 0.5 was assigned for
low clonality mutations and 1 for high clonality muta-
tions using proportional odds logistic regression
(POLR), as previously described [3]. The presence of
MSI was also assigned a proportional value using
POLR. The proportional value of MSI present at a
single genomic locus was 0.75. The proportional value
of each additional MSI present, beyond one locus, was
0.5. These numerical values for low clonality and high
clonality LOH mutations (Fig. 1a) as well as MSI
mutations (Fig. 1b) were added together for all loci
containing LOH and/or MSI in a microdissected target.
The resulting cumulative value was defined as the ML
for that microdissected target.
Polyserial correlation coefficient was used to examine the
correlation between histological class and ML of microdis-
sected targets when ML was assessed using only LOH muta-
tions (Fig. 1a) or both LOH and MSI mutations (Fig. 1b). An
analysis of variance (ANOVA) model was used to examine
the difference inML between advanced (HGD, EAC) and less
advanced (IM, IND, LGD) histological classifications when
ML included only LOH analysis as compared to when it
included both LOH and MSI analysis. ANOVA was per-
formed with an interaction term between the two methods of
ML assessment (LOH only, LOH and MSI) and the two
categories of histological classifications of BE (advanced
histology, less advanced histology).
Three levels of ML were defined using the distribution of
ML present in the population of targets with IM histology. (1)
"No ML" contained microdissected targets that lacked muta-
tions. (2) "Low ML" contained targets that had mutations, but
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the level of ML in this category was below the top 5th
percentile of IM targets that had the highest ML. (3) "High
ML" contained microdissected targets with an ML similar to
those targets in the top 5th percentile of IM targets with the
highest ML. These levels of ML were applied to all histolog-
ical classifications.
Results
The Presence of LOH andMSI in Histological Classifications
Mutational analysis was performed on 877 microdis-
sected targets corresponding to 661 esophageal biopsy
slides from 415 patients. The average number of low
clonality and high clonality LOH mutations and MSI
mutations in microdissected targets generally increased
with increasingly severe histology (Table 1). MSI mu-
tations occurred less often than LOH mutations, but
generally increased with increasingly severe histologi-
cal classifications. LOH mutations were also most
abundant in targets with dysplastic histology and oc-
curred on average more often than MSI in HGD and
EAC. Low clonality LOH and MSI mutations were
detected in similar or higher abundance than high
clonality LOH mutations in less severe histological
classifications (IM, IND, LGD), suggesting these mu-
tations may occur prior to the appearance of more
advanced histological stages of BE.
Mutations were observed across the entire panel of geno-
mic loci examined. Table 2 describes the percentages of
microdissected targets mutated at each of the ten genomic loci
for each histological classification. The percentages of LOH
and MSI mutated targets generally increased with more ad-
vanced histological classifications, from COL to HGD. Im-
portantly, LOH and MSI mutations at all loci were detected
with less advanced stages of BE histology (IM, IND, LGD)
but were found more frequently with more advanced stages of
BE histology (HGD, EAC). In less advanced BE histology
(IM, IND), the most frequently LOHmutated loci included 9p
(CDKN2A), 10q (PTEN,MXI1), and 17p (TP53), 17q (NME1),
which is consistent with previous studies [3, 21, 22, 28]. MSI
mutations at nearly all loci occurred at a similar frequency in
less advanced stages of BE histology. In targets with COL,
limited MSI and LOH mutations were observed across the
panel of loci examined.
Fig. 1 Correlation of mutational load (ML) to histological classification
of microdissected targets a based on the presence and extent of low and
high clonality LOH mutations only (correlation coefficient=0.68,
p<0.0001) and b based on the presence and extent of low and high
clonality LOH mutations as well as MSI (correlation coefficient=0.69,
p<0.0001). COL columnar mucosa, IM intestinal metaplasia, IND indef-
inite for dysplasia, LGD low-grade dysplasia,HGDhigh-grade dysplasia,
EAC esophageal adenocarcinoma
Table 1 Average number of mutations detected in microdissected targets with each histology
Histological classification Total micro.
targets tested
Average number of mutated
loci detected per micro. target
Average number of low/high clonality LOH and MSI




COL 99 0.5 0.5 0.0 0.0 0.3
IM 427 1.1 0.7 0.1 0.3 0.7
IND 182 1.9 1.4 0.3 0.2 1.1
LGD 85 2.7 1.7 0.6 0.5 1.8
HGD 61 4.3 2.2 1.6 0.8 3.2
EAC 23 5.9 4.3 1.3 0.8 3.9
COL columnar mucosa, IM intestinal metaplasia, IND indefinite for dysplasia, LGD low-grade dysplasia, HGD high-grade dysplasia, EAC esophageal
adenocarcinoma, Micro.microdissected
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Pathologist Variability Amongst Histological Classifications
To understandwhich histologywasmost reliably classified for
each microdissected target, the agreement amongst three pa-
thologists was examined in one study cohort (Table 3). Con-
sistent with previous reports, most disagreement was linked to
IND and LGD histology, where in the majority of microdis-
sected targets at least one pathologist disagreed with another
(100 % IND and 88 % LGD) [15]. By contrast, all three
pathologists agreed on the histological classification of IM
in the majority of microdissected targets (69 %). In 50 % of
microdissected targets all pathologists agreed in classifying
HGD, while in the other 50 % of targets one disagreed,
consistent with previously published studies describing vari-
ability amongst HGD calls [14].
Assessment of Genomic Instability
The presence and extent (clonality) of genomic instability in
each microdissected target was assessed by ML. The ML of a
target was calculated based on the presence and clonality of
LOH mutations as well as the presence of MSI in DNA from
each histological target. In this system, numerical values were
determined by POLR as follows: 0.5 for low clonality LOH
mutations (50–75 % of DNA had LOH), 0.75 for the first
MSI, 0.5 for each additional MSI, and 1 for high clonality
LOH mutations (>75 % of DNA had LOH). These numerical
values for low clonality LOH, MSI, and high clonality LOH
mutations were added together for all loci in a microdissected
target. The resulting cumulative value was defined as the
mutation load for that microdissected target. Consistent with
Table 2 The percent microdissected targets with mutations each at each genomic loci by histological classification
Mutation Loci Tumor suppressor
genes (TSG)













MSI 1p CMM1, LMYC 1 – 2 1 7 9
3p VHL, OGG1 – 7 3 11 13 3
5q MCC, APC – 3 3 7 – 4
9p CDKN2A 2 2 – 1 13 –
10q PTEN, MXI1 – 1 3 2 10 9
17p TP53 – 4 2 7 7 9
17q NME1 – 2 3 14 11 4
18q DCC – 5 1 1 10 4
21q TFF1, PSEN2 – 3 – 1 – –
22q NF2 – 2 – 4 5 4
LOH 1p CMM1, LMYC 1 5 14 19 34 43
3p VHL, OGG1 2 5 18 27 41 61
5q MCC, APC 11 8 18 20 34 61
9p CDKN2A 7 32 36 45 72 61
10q PTEN, MXI1 10 7 22 8 15 43
17p TP53 11 11 29 49 87 83
17q NME1 2 7 22 26 21 65
18q DCC – 1 1 11 38 78
21q TFF1, PSEN2 5 5 12 24 21 13
22q NF2 – 2 1 5 15 48
COL columnar mucosa, IM intestinal metaplasia, IND indefinite for dysplasia, LGD low-grade dysplasia, HGD high-grade dysplasia, EAC esophageal
adenocarcinoma, – 0 % targets mutated
Table 3 Frequency of patholo-
gist agreement on histological
classification in one study cohort
IM intestinal metaplasia, IND in-
definite for dysplasia, LGD low-








IM (N=115) 69 30 1
IND (N=19) 0 63 37
LGD (N=8) 13 88 0
HGD (N=4) 50 50 0
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a recent publication in a smaller dataset, the ML of microdis-
sected targets positively correlated with increasingly severe
histology (Fig. 1) [3]. However, ML in this past publication
was only assessed using the presence of low and high clonality
LOH mutations. The correlation of increasingly severe histol-
ogy to ML based on the presence of low and high clonality
mutations alone is shown in Fig. 1a (correlation coefficient=
0.68, p<0.0001). When a weighted value for MSI mutations
was included in the assessment of ML (Fig. 1b), the positive
correlation between ML and increasingly severe histology
was slightly improved (correlation coefficient=0.69,
p<0.0001). Importantly, the addition ofMSI to the assessment
of ML helped to better discriminate the difference in ML
between less advanced (IM, IND, LGD) and more advanced
(HGD, EAC) histological classifications of BE (Fig. 1a vs.
Fig. 1b). The average difference inML between less advanced
histology (IM, IND, LGD) and more advance histology
(HGD, EAC) was statistically higher when both LOH and
MSI was considered as compared to only LOH (2.54 vs. 2.21,
p=0.02).
Using the distribution of ML present in the population of
targets with IM histology, three levels of ML were established
with respect to histological classifications when both LOH
and MSI were included in the assessment of ML (Table 4).
The first level contained microdissected targets that lacked
mutations and, as such, had "no ML". The second level ("low
ML") contained targets with an ML found in the majority of
IM microdissected targets. LowML targets had mutations but
were below the top 5th percentile of IM targets with the
highest ML. The third level ("high ML") contained microdis-
sected targets with anML similar to those targets in the top 5th
percentile of IM targets with the highest ML.
Table 4 summarizes the proportion of microdissected tar-
gets for each level of ML in each histological class. The
majority of microdissected histological targets composed of
COL had no Detectable ML (Table 4, no ML). Of the propor-
tion of non-BE targets (COL) that had mutations, all but one
were lowML. Of the INDmicrodissected targets 18 % had no
ML, while the remaining proportion of IND targets had mu-
tations, including 66 % that had low ML and 16 % that had
highML.Most microdissected targets histologically classified
as LGD had mutations with the majority of targets falling into
the lowML (46 %) or highML (46 %) levels. Nearly all HGD
(95 %) and EAC (96 %) histological targets had high ML.
Comparatively, only 8 % of IM and 16 % of IND microdis-
sected targets were characterized as having a high ML.
Discussion
Current risk stratification of BE patients for EAC relies on
histological classification and grade of dysplasia. However,
histological classification alone cannot sufficiently assess the
risk of patients with variable or non-dysplastic BE histology
[2, 29]. Progression of BE patients to EAC is associated with
accumulated genomic instability [4, 30]. We therefore exam-
ined differences in the presence and extent of genomic insta-
bility in advanced and less advanced stages of BE histology.
Genomic instability was assessed by ML, accounting for the
presence and clonality of LOH as well as the presence of MSI
in ten genomic loci around tumor suppressor genes associated
with EAC (Tables 1 and 2). Our results demonstrate that
histology-guided assessment for ML provided an objective
measure of genomic instability amongst BE histological
classifications.
Consistent with previous work, increasing ML correlated
with increasingly severe BE histology (Table 1, Fig. 1) [3].
The addition of MSI characterization at each of the ten geno-
mic loci to the assessment of ML slightly increased this
correlation (Fig. 1a and b). Studies have published conflicting
results regarding the association ofMSI and EAC [31, 32].We
therefore examined MSI at BAT25 and BAT26 in a subset of
microdissected targets (N=71). In this subset, MSI at BAT25
or BAT26 was detected in 4/43 microdissected targets histo-
logically classified as HGD or EAC (data not shown). How-
ever, MSI in these markers was not detected in less severe BE
histology (IM, IND, LGD), suggesting that MSI at these loci
had little predictive value concerning disease progression in
this subset. By contrast, the appearance of new alleles indic-
ative of MSI was consistently observed in the microsatellite
repeats of the ten genomic loci in which LOH was also
examined, both in less advanced (IM, IND, LGD) and more
advanced histological classifications (HGD, EAC) (Table 2).
To our knowledge, this is the first report of MSI related to BE
in these microsatell i tes, which are composed of
tetranucleotide repeats. The novel detection of MSI at these
ten loci in less severe histological classifications of BE (IM,
IND, LGD) could be a result ofMSI produced bymechanisms
different than those associatedwith BAT25 and BAT26mono-
nucleotide repeats, which involve disruption of DNA repair





% No ML % Low ML % High ML
COL (N=99) 61 38 1
IM (N=427) 30 62 8
IND (N=182) 18 66 16
LGD (N=85) 8 46 46
HGD (N=61) 0 5 95
EAC (N=23) 0 4 96
COL columnar mucosa, IM intestinal metaplasia, IND indefinite for
dysplasia, LGD low-grade dysplasia, HGD high-grade dysplasia, EAC
esophageal adenocarcinoma
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(hMLH1/hMSH2) functions. In general, MSI at these ten
genomic loci slightly increased with increasingly severe his-
tology (Table 2). More importantly, the addition of MSI to the
assessment of ML helped to better stratify the difference
in ML between less advanced (IM, IND, LGD) and
more advanced (HGD, EAC) histological classifications
of BE (Fig. 1).
We defined three levels of ML (no, low, and high ML),
when MSI mutations and low and high clonality LOH muta-
tions were assessed. These three levels were determined using
the heterogeneous distribution of ML present in the popula-
tion of targets with IM histology (N=427). The levels were
then applied to each histological classification to determine
the proportion of targets captured in each level (Table 4). The
three levels were stratified using the distribution of ML in IM
targets, because IM histology was the most reliably classified
histology amongst all three pathologist in the subset of micro-
dissected targets analyzed here, which has also been observed
by others (Table 3) [14, 17].
High, low, and no levels of ML captured relatively similar
proportions of microdissected targets with each histology as
compared to that of a past single cohort study [3]. Importantly,
microdissected targets with HGD (95 %) or EAC (96 %)
consistently had high ML (Table 4) and about half of LGD
(46 %) histological targets had high ML in both studies.
Although the presence of HGD and confirmed LGD are risk
factors for progression to EAC, lack of pathologist agreement
concerning LGD and IND histological classifications, as ob-
served here and in other studies, suggests a need for addition-
al, more objective clinical information when such diagnoses
are encountered (Table 3) [11, 13, 29]. ML can provide
information about genomic instability for these inconsistent
histological classifications of BE.
Roughly half of the histological targets (44 %) with high
ML had high risk or severe histological classifications (HGD,
EAC), while the other half (56 %) had less severe histology
(COL, IM, IND, LGD). Importantly, a proportion of non-
dysplastic BE targets with IM (8 % high ML) and IND
(16 % high ML) histology had a similar ML as those with
HGD and EAC histology (Table 4). Therefore, this portion of
targets had molecular changes that are similar to those seen
with high risk and severe disease (HGD, EAC), which is
consistent with that observed in previous work concerning
ML [3]. High ML in less severe histological classifications of
BE may be indicative of imminent morphological changes
that have yet to become visible by histology. A relatively high
load of molecular changes, which occurs in a fraction of
microdissected targets with less advanced histology, may help
to more objectively identify targets that are more likely to
develop into advanced BE histology (HGD or EAC).
By contrast, mutations were not always present in micro-
dissected targets with less severe histology (COL, IM, IND,
LGD). The proportion of microdissected targets that lacked
mutations (no ML) decreased with increasingly severe histol-
ogy (Table 4), consistent with previous work describing ML
[3]. Importantly, lack of mutations (no ML) was not detected
in any microdissected targets with HGD or EAC histology.
Because the loci examined in this study are a survey of
genomic sites relevant to Barrett's associated EAC, the ab-
sence of clonally expanded LOH mutations and MSI muta-
tions next to these ten relevant genomic loci provides strong
evidence that the histological targets examined did not have
extensive genomic instability related to BE. Therefore, the
lack ofML (noML) in a portion of BE targets with less severe
histology is likely indicative of benign biological processes. In
addition, low levels of mutations (low ML) were present in
COL, suggesting that the presence of a few mutations alone is
not necessarily indicative of higher risk histological disease.
Our study is consistent with others describing genomic
instability around TP53 and CDKN2A tumor suppressor
genes, which has been associated with greater risk of BE
histological progression to EAC [21, 22, 28]. Similar to these
studies, LOH in the microsatellite regions of TP53 and
CDKN2A tumor suppressor genes were included in our panel.
LOH mutations in these loci were found most frequently in
microdissected targets with histological dysplasia (Table 2).
However, consistent with previous work, many additional
genomic loci also had LOH in dysplastic targets and targets
with EAC, suggesting that all loci are relevant to progressive
Barrett's disease [3]. Furthermore, many genomic loci had
LOH mutations in non-dysplastic targets (IM, IND) in com-
parable frequency to CDKN2A and TP53 associated muta-
tions, suggesting that other genomic loci beyond those related
to TP53 and CDKN2A are present at even early stages of BE.
Similarly, MSI mutations at these ten genomic loci occurred
more often in dysplastic microdissected targets but were also
present in non-dysplastic targets across nearly all loci.
While the strengths of this study have demonstrated that
ML can provide an objective measure of the presence and
extent of genomic instability amongst BE histological classi-
fications, there are study limitations to consider. Limitations in
this study include those inherent to studies correlating infor-
mation to histological diagnoses. Due to variability in pathol-
ogist diagnoses, there is unavoidable variability in the histo-
logical classification used as the reference standard when
correlating molecular results. However, when consensus his-
tological classification was compared to ML in a subset of
microdissected targets, the correlation between histological
diagnosis and ML was still observed (data not shown), al-
though only limited dysplastic histological targets were avail-
able for multiple pathologist review in this subset. Moreover,
this study is cross-sectional. Further studies are required, and
ongoing, to determine how accurately levels of ML described
herein can differentiate patients who have less severe BE
histology (IM, IND, LGD) and will progress from those
who will not progress over time.
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The results of this study support the use ofML assessments
in conjunction with histological classification of BE to better
manage patients. ML assesses the presence and extent of
genomic instability, which has been associated with increased
risk of progression to EAC [4, 30]. A portion of microdissect-
ed targets with non-dysplastic histological classifications
shared a similar ML as those with higher risk disease (HGD)
and even EAC. Given that EAC is associated with accumu-
lated genomic instability, high ML in less severe histological
diagnoses may be an indication of BE disease at higher risk of
progression to EAC. Therefore, ML may help to better man-
age BE patients in early stages of disease and when histolog-
ical diagnosis provides insufficient information. Incorporating
assessments for ML in patient management may help to
reduce health economic costs and increase patient quality of
life by limiting unnecessary clinical interventions and frequent
surveillance in patients destined for non-malignant disease
and by allowing earlier and less morbid intervention in pa-
tients destined for malignancy.
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